Experience

Eurogentec

• Belgium
• Biotechnology Research
• 200 - 300 Employee

• Biologics Business Developer

  • Jan 2021 - Present

  I am responsible for new client businesses and new opportunities/technologies for the Biopharma business unit (Plasmid DNA, Protein and IVT RNA [mRNA, gRNA, saRNA, LongRNA] GMP manufacturing). My sales territory extends from Europe and UK to the north USA and Canada. I am in direct contact with biotech (small, medium) and big pharma for lead qualification, prospection, company business presentation, and description, initial project planning, price offer, contract/MSA negotiation, and signature. Show less



Université catholique de Louvain

• Belgium
• Research Services
• 700 & Above Employee

• Business Developer

  • Jan 2020 - Jan 2021



Université de Namur

• Belgium
• Higher Education
• 700 & Above Employee

• Porteur de projet First Spin Off

  • Oct 2016 - Jan 2020



QUALIblood s.a.

• Belgium
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Co-Founder

  • Nov 2017 - Oct 2018

  Define a business model and a business plan. Fundraising and discussion with investor, client and prospects. Patent and license negotiation. Define a business model and a business plan. Fundraising and discussion with investor, client and prospects. Patent and license negotiation.



CHU UCL Namur

• Belgium
• Hospitals and Health Care
• 700 & Above Employee

• Post Doc researcher on EU Programme

  • Oct 2015 - Oct 2016



Université catholique de Louvain

• Belgium
• Research Services
• 700 & Above Employee

• PhD Student

  • Oct 2011 - Sep 2015

  Project: study of the underlying mechanism of the hypercoagulable state in acute leukemia and impact of specific treatments on the thrombotic risk Goal: Help clinicians to predict thrombotic risk in leukemic patient with a new biomarker Tasks and functions: Characterization of microvesicles derived from tumor cells, (morphology, activity and sizing). Clinical study on the use of microvesicles as biomaker for thrombotic risk in patient with acute leukemia. Experiment; method development; scientific articles and ethical protocols writing; statistical analysis; Clinical study protocols writing; follow-up of leukemic patient during 2 years; results presentation (congress and private society) Show less